Drugs / FEXAPOTIDE
FEXAPOTIDE
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01620515 | Feb 2012 → Oct 2015 | prostate cancer | Nymox Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00759135 | May 2007 → Jan 2008 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT02003742 | Sep 2013 → Jan 2015 | — | RECORDATI GROUP | Terminated | No outcome recorded |
| Phase 3 | NCT01846793 | Apr 2013 → Oct 2014 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01438775 | Sep 2011 → Jan 2013 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00945490 | May 2009 → May 2014 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00918983 | Apr 2009 → Nov 2013 | benign prostatic hyperplasia | Nymox Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FEXAPOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Known as | Fexapotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Known as | NX-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00918983 ↗ |
| Known as | NYM-4805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545061 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3545061 ↗ |
| Route | Other | “single intraprostatic injection of 2.5 mg NX-1207” NCT00759135 ↗ |